Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 2/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31556400 | 0.89 | NPY1R (0.59) | OPRD1NTSR1NTSR2SORT1NPY1R | |
| SCHEMBL30445290 | 0.87 | OPRD1 (0.59) | OPRD1NTSR1NTSR2SORT1OPRM1 | |
| SCHEMBL14060698 | 0.86 | NPY1R (0.55) | OPRD1NTSR1NTSR2SORT1NPY1R | |
| SCHEMBL29611692 | 0.85 | NPY1R (0.62) | OPRD1NTSR1NTSR2SORT1NPY1R | |
| SCHEMBL29611528 | 0.85 | NPY1R (0.62) | OPRD1NTSR1NTSR2SORT1NPY1R | |
| SCHEMBL29611824 | 0.85 | NPY1R (0.62) | OPRD1NTSR1NTSR2SORT1NPY1R | |
| SCHEMBL29387174 | 0.85 | NPY1R (0.62) | OPRD1NTSR1NTSR2SORT1NPY1R | |
| SCHEMBL29611985 | 0.85 | NPY1R (0.62) | OPRD1NTSR1NTSR2SORT1NPY1R | |
| SCHEMBL20707335 | 0.85 | NPY1R (0.62) | OPRD1NTSR1NTSR2SORT1NPY1R | |
| SCHEMBL29611524 | 0.85 | NPY1R (0.62) | OPRD1NTSR1NTSR2SORT1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939404-B2 | Method for producing cyclized peptide having intramolecular S-S bond | AJINOMOTO CO., INC. (JP) | 2024-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939404-B2 | Method for producing cyclized peptide having intramolecular S-S bond | SPPL2B, PTMS, VIP | OXTR 1734/4885OPRD1 4643/4885NTSR1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.